Exhibit 99.1
AMARIN CORPORATION PLC
LONDON, United Kingdom, December 12, 2006 , Amarin Corporation plc (“Amarin” or "Company") announces that it granted the
following stock options to the following directors on December 8, 2006 in accordance with the Company’s 2002 Stock Option Plan:
About Amarin
Amarin is a neuroscience company focused on the research, development and commercialisation of novel drugs for the treatment of central
nervous system disorders. Amarin has a late-stage drug development pipeline. Miraxion, Amarin’s lead development compound, is in Phase
III development for Huntington’s disease, Phase II development for depressive disorders and preclinical development for Parkinson’s
disease. Amarin’s core development pipeline also includes the recently acquired global rights to a novel oral formulation of apomorphine for
treating patients with advanced Parkinson’s disease.
Miraxion for Huntington’s disease is being developed under a Special Protocol Assessment agreed with the US Food and Drug
Administration (“FDA”), has been granted Fast Track designation by the FDA and has received Orphan Drug designation in the US and
Europe.
Amarin maintains its primary stock market listing in the US on NASDAQ (“AMRN”) and secondary listings in the UK and Ireland on AIM
(“AMRN”) and IEX (“H2E”) respectively.
For press releases and other corporate information, visit the Amarin website at http://www.amarincorp.com . Information on our website
does not form part of this press release.
Director
Number of stock
options over Ordinary
Shares/ADSs granted
Exercise Price per
Ordinary Share/ADS
Expiration date of stock
options
(mm/dd/yy)
Total number of
stock options held
by director
following this grant
Mr Richard Stewart
800,000
$2.30
12/08/16
2,050,000
Mr Alan Cooke
675,000
$2.30
12/08/16
1,450,000
Mr John Groom
20,000
$2.30
12/08/16
95,000
Dr William Mason
20,000
$2.30
12/08/16
80,000
Mr Anthony Rus